Salvarani C.,Unit of Rheumatology |
Salvarani C.,Rheumatology Unit |
Hunder G.G.,Rochester College
Current Opinion in Rheumatology | Year: 2012
Our better understanding of the PCNSV spectrum and its subsets will facilitate early recognition. This may facilitate earlier treatment and may prevent irreversible or even lethal outcomes. Copyright © Lippincott Williams & Wilkins.
Lubrano E.,University of Molise |
Cantini F.,Unit of Rheumatology |
Costanzo A.,University of Rome La Sapienza |
Girolomoni G.,University of Verona |
And 8 more authors.
Autoimmunity Reviews | Year: 2015
Psoriasis is a common, immune-mediated chronic inflammatory disease with a primary involvement of skin and joints, affecting approximately 2% of the population worldwide. Up to one third of patients with psoriasis are diagnosed with psoriatic arthritis (PsA). Psoriasis and PsA are heterogeneous diseases whose severity depends on a number of clinical factors, such as areas affected and pattern of involvement, and are associated with a range of comorbid diseases and risk factors, including obesity, metabolic syndrome, cardiovascular disease and liver disease. Thus measuring the severity of psoriatic disease needs to take into account the multidimensional aspects of the disease. Subjective measures including the impairment in quality of life or in daily living activities as well as the presence of cardio-metabolic comorbidities, are important for the outcome and add further levels of complexity that, to a certain extent, need to be assessed. Because of the wide range of comorbid conditions associated with psoriasis, comprehensive screening and treatment must be implemented for a most effective managing of psoriasis patients. A joint dermatologist-rheumatologist roundtable discussion was convened to share evidence on the real-life use of methods for measuring psoriasis severity comprehensively. Our objective was to provide an expert position on which clinical variables are to be taken into account when considering patients affected by psoriasis and/or PsA globally and on the assessment tools more suitable for measuring disease activity and/or severity in clinical practice. © 2015 Elsevier B.V.
Branco J.C.,Hospital Egas Moniz |
Bannwarth B.,Groupe Hospitalier Pellegrin |
Failde I.,University of Cádiz |
Abello Carbonell J.,Hospital del Mar |
And 9 more authors.
Seminars in Arthritis and Rheumatism | Year: 2010
Objective: A survey was performed in 5 European countries (France, Germany, Italy, Portugal, and Spain) to estimate the prevalence of fibromyalgia (FM) in the general population. Methods: In each country, the London Fibromyalgia Epidemiological Study Screening Questionnaire (LFESSQ) was administered by telephone to a representative sample of the community over 15 years of age. A positive screen was defined as the following: (1) meeting the 4-pain criteria alone (LFESSQ-4), or (2) meeting both the 4-pain and the 2-fatigue criteria (LFESSQ-6). The questionnaire was also submitted to all outpatients referred to the 8 participating rheumatology clinics for 1 month. These patients were examined by a rheumatologist to confirm or exclude the FM diagnosis according to the 1990 American College of Rheumatology classification criteria. The prevalence of FM in the general population was estimated by applying the positive-predictive values to eligible community subjects (ie, positive screens). Results: Among rheumatology outpatients, 46% screened positive for chronic widespread pain (LFESSQ-4), 32% for pain and fatigue (LFESSQ-6), and 14% were confirmed FM cases. In the whole general population, 13 and 6.7% screened positive for LFESSQ-4 and LFESSQ-6, respectively. 3The estimated overall prevalence of FM was 4.7% (95% CI: 4.0 to 5.3) and 2.9% (95% CI: 2.4 to 3.4), respectively, in the general population. The prevalence of FM was age- and sex-related and varied among countries. Conclusion: FM appears to be a common condition in these 5 European countries, even if data derived from the most specific criteria set (LFESSQ-6) are considered. © 2010.
D'Alto M.,The Second University of Naples |
Ghio S.,Fondazione IRCCS Policlinico S. Matteo |
D'Andrea A.,The Second University of Naples |
Pazzano A.S.,Fondazione IRCCS Policlinico S. Matteo |
And 9 more authors.
Heart | Year: 2011
Background: Recent data show that there is an unexpectedly high prevalence of 'inappropriate' pulmonary responses to exercise among patients with systemic sclerosis (SS). However, no consensus exists as to which threshold of pulmonary artery systolic pressure (PASP) can be considered diagnostically relevant. Aim: To evaluate pulmonary vascular reserve and right ventricular function changes induced by exercise in SS patients without overt pulmonary arterial hypertension. Methods and results: The study enrolled 172 consecutive SS patients in NYHA class I - II, with a peak tricuspid regurgitant jet velocity at echocardiography not greater than 3 m/s, and 88 control subjects. Echocardiography was performed at rest and at the end of a maximal exercise test. SS patients showed a higher exercise-induced PASP than control subjects (36.9±8.7 vs 25.9±3.3 mm Hg, p=0.00008). The response to effort was higher in the presence of moderate interstitial lung disease (39.7±9.3 vs 36.0±8.4 mm Hg, p=0.016) or subclinical left ventricular diastolic dysfunction (42.3±5.8 vs 37.0±8.6 mm Hg, p=0.015). In control subjects, PASP values were normally distributed at rest and after exercise. In SS patients, the distribution was normal at rest but bimodal after exercise, with a second peak at 52.2 mm Hg including 13% of the total SS population. Patients in this subgroup showed subtle abnormalities of right ventricular function at rest and, most importantly, a blunted increase in right ventricular systolic function with exercise. Conclusion: Exercise echocardiography may identify a subset of SS patients with an inappropriate exercise-induced increase in PASP and early signs of right ventricular dysfunction.
Valentini G.,Unit of Rheumatology |
Vettori S.,Unit of Rheumatology |
Cuomo G.,Unit of Rheumatology |
Iudici M.,Unit of Rheumatology |
And 5 more authors.
Arthritis Research and Therapy | Year: 2012
Introduction: We investigated early systemic sclerosis (SSc) (that is, Raynaud's phenomenon with SSc marker autoantibodies and/or typical capillaroscopic findings and no manifestations other than puffy fingers or arthritis) versus undifferentiated connective tissue disease (UCTD) to identify predictors of short-term disease evolution.Methods: Thirty-nine early SSc and 37 UCTD patients were investigated. At baseline, all patients underwent clinical evaluation, B-mode echocardiography, lung function tests and esophageal manometry to detect preclinical alterations of internal organs, and were re-assessed every year. Twenty-one early SSc and 24 UCTD patients, and 25 controls were also investigated for serum endothelial, T-cell and fibroblast activation markers.Results: At baseline, 48.7% of early SSc and 37.8% of UCTD patients had at least one preclinical functional alteration (P > 0.05). Ninety-two percent of early SSc patients developed manifestations consistent with definite SSc (that is, skin sclerosis, digital ulcers/scars, two or more teleangectasias, clinically visible nailfold capillaries, cutaneous calcinosis, X-ray bibasilar lung fibrosis, X-ray esophageal dysmotility, ECG signs of myocardial fibrosis and laboratory signs of renal crisis) within five years versus 17.1% of UCTD patients (X2= 12.26; P = 0.0005). Avascular areas (HR = 4.39 95% CI 1.18 to 16.3; P = 0.02), increased levels of soluble IL-2 receptor alpha (HR = 4.39; 95% CI 1.03 to 18.6; P = 0.03), and of procollagen III aminopropeptide predicted disease evolution (HR = 4.55; 95% CI 1.18 to 17; P = 0.04).Conclusion: Most early SSc but only a few UCTD patients progress to definite SSc within a short-term follow-up. Measurement of circulating markers of T-cell and fibroblast activation might serve to identify early SSc patients who are more likely to develop features of definite SSc. © 2012 Valentini et al.; licensee BioMed Central Ltd.
De Stefano R.,Unit of Rheumatology |
Frati E.,Unit of Rheumatology |
De Quattro D.,Unit of Rheumatology |
Menza L.,Unit of Rheumatology |
Manganelli S.,Unit of Rheumatology
Clinical Rheumatology | Year: 2014
We wanted to do a prospective open-label study to evaluate if ankylosing spondylitis (AS) patients in clinical remission with twice weekly etanercept (ETN) 25 mg therapy could be changed to weekly regimen or even to every other week regimen without increased dose for injection. Thirty-eight AS patients self-administered 25 mg of ETN (Wyett) subcutaneously. According to the protocol, patients who were in clinical partial remission with twice weekly ETN 25 mg at week 12 and 16 changed to a weekly regimen without a change of the dose. If clinical remission, despite the reduction of the dose, persists at week 24 and 28, patients changed to an every-other-week regimen, continuing with this administration schedule for the entire duration of the study if at week 36 and 46 clinical remission was maintained. At the end of the study, 18 patients (47%) were still in remission, 4 (10%) with a weekly regimen, and 14 (37%) with an every-other-weekly regimen. Our study indicates that a consistent percentage of subjects with AS, treated with ETN 25 mg twice weekly, achieved clinical remission within the first 3 months of therapy, and also, a substantial percentage of these patients maintains the partial remission with an every other week regimen. © Clinical Rheumatology 2013.
Guillodo Y.,Unit of Rheumatology
Foot & ankle specialist | Year: 2010
Ankle sprains may be followed by chronic pain and/or instability, which may induce substantial disability, most notably in athletes. Chronic ankle instability promotes the development of cartilage lesions in athletes. Therefore, accurate evaluation of the ankle ligaments is crucial to the optimal management of chronic ankle instability after a sprain. The objective of this study was to assess the performance of ultrasonography in assessing damage to the anterior talofibular ligament (ATFL) in athletes with chronic ankle instability after a sprain. Consecutive patients seen at the author's clinic for ankle instability more than 3 months after a sprain underwent ultrasonography and computed arthrotomography after a clinical anterior drawer stress test. Cohen's kappa was computed to evaluate agreement between the 2 imaging modalities. This study included 56 patients, 46 men and 10 women, aged 15 to 69 years (mean, 30.1 ± 10.6 years). Mean time from the sprain to imaging was 7.6 ± 4.02 months. ATFL damage was found by ultrasonography in 34 (61%) of 56 patients and by computed arthrotomography in 39 of 55 patients (71%; κ = 0.76). Cartilage damage was visualized by computed arthrotomography in 14 (25%) patients, all of whom had ATFL damage. Agreement was substantial (κ = 0.76) between ultrasonography and computed arthrotomography for assessing the ATFL. The data support the use of ultra-sonography as the second-line investigation after a standard radiographic assessment in athletes with chronic ankle instability after a sprain.
Salvarani C.,Unit of Rheumatology |
Brown Jr. R.D.,Mayo Medical School |
Hunder G.G.,Rochester College
The Lancet | Year: 2012
Primary CNS vasculitis is an uncommon disorder of unknown cause that is restricted to brain and spinal cord. The median age of onset is 50 years. The neurological manifestations are diverse, but generally consist of headache, altered cognition, focal weakness, or stroke. Serological markers of inflammation are usually normal. Cerebrospinal fluid is abnormal in about 80-90% of patients. Diagnosis is unlikely in the presence of a normal MRI of the brain. Biopsy of CNS tissue showing vasculitis is the only definitive test; however, angiography has often been used for diagnosis even though it has only moderate sensitivity and specificity. The size of the affected vessels varies and determines outcome and response to treatment. Early recognition is important because treatment with corticosteroids with or without cytotoxic drugs can often prevent serious outcomes. The differential diagnosis includes reversible cerebral vasoconstriction syndromes and secondary cerebral vasculitis.
Canas C.A.,Unit of Rheumatology |
Echeverri A.F.,Unit of Rheumatology |
Anaya J.-M.,El Rosario University
Open Rheumatology Journal | Year: 2012
Based on the observation of a patient with a causal relationship between hyperparathyroidism and development of both autoimmune disease and paraproteinemia, we hypothesize a novel cause of autoimmunity triggered in the context of hyperparathyroidism. © Cañas et al.; Licensee Bentham Open.
PubMed | Unit of Rheumatology
Type: Case Reports | Journal: The British journal of dermatology | Year: 2016
We present two cases of patients with systemic autoimmune diseases (one with dermatomyositis and one with CREST syndrome) who presented with a worsening of calcinosis cutis after treatment of osteoporosis with teriparatide. To our knowledge, this association is not described in the literature and might be considered in the spectrum of adverse reactions to teriparatide.